JPMorgan Chase & Co. Has Lowered Expectations for Cellebrite DI (NASDAQ:CLBT) Stock Price

Cellebrite DI (NASDAQ:CLBT - Free Report) had its price objective reduced by JPMorgan Chase & Co. from $29.00 to $25.00 in a research report released on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a report on Wednesday, April 2nd. Lake Street Capital lifted their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI presently has an average rating of "Buy" and a consensus target price of $22.43.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock traded up $0.14 during trading on Monday, reaching $17.41. The company's stock had a trading volume of 1,845,732 shares, compared to its average volume of 1,461,446. The business's fifty day moving average price is $19.02 and its 200-day moving average price is $20.23. The firm has a market cap of $4.17 billion, a price-to-earnings ratio of -12.53, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI has a one year low of $10.25 and a one year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Sell-side analysts anticipate that Cellebrite DI will post 0.3 EPS for the current year.

Institutional Trading of Cellebrite DI

Institutional investors and hedge funds have recently made changes to their positions in the business. Assetmark Inc. acquired a new position in shares of Cellebrite DI in the 1st quarter valued at $33,000. Catalyst Capital Advisors LLC bought a new stake in Cellebrite DI during the 1st quarter worth about $51,000. Virtus Advisers LLC bought a new stake in shares of Cellebrite DI in the 1st quarter valued at about $63,000. Gen Wealth Partners Inc bought a new stake in shares of Cellebrite DI in the 4th quarter valued at about $85,000. Finally, NewEdge Advisors LLC raised its holdings in shares of Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after purchasing an additional 3,352 shares during the period. Institutional investors own 45.88% of the company's stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.